Caris Life Sciences Reports $1.04 Quarterly Revenue
Caris Life Sciences reported quarterly results highlighted by raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%, according to its earnings release filed with an 8-K Wednesday.
Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period. Reported net income of $15.3 million. Reported positive Adjusted EBITDA of $44.4 million. Reported net cash used in operating activities of $22.2 million, and free cash flow of $(39.7) million.
David Dean Halbert said, "This was another record quarter, with 61,500 clinical cases, up 21% year over year,"
Results detail
Further figures in the release included Share repurchase program of up to $100.0 million, of which $72.1 million remains available for repurchase under the existing Board authorization; Total revenue was $275.4 million for the three months ended September 30, 2026, compared to $216.8 million for the three months ended September 30, 2025, an increase of $58.5 million, or 27%.
The filing is an Item 2.02 results announcement furnished with Exhibit 99.1. Comparisons use the year-earlier period as presented by Caris Life Sciences unless the release specifies another baseline. Where both GAAP and non-GAAP metrics appear, both are summarized when the extract includes them.
Segment mix, cash flow and any outlook language in the release are the usual secondary reads after the headline revenue and earnings figures. One-time items—restructuring, impairments, gains on sales or legal settlements—can move GAAP profit without changing the run-rate story, so reconciliations remain essential.
Why it matters
For retail investors, the Caris Life Sciences print is a check on whether growth, margins and cash generation are moving together. The figures above come from the company’s Exhibit 99.1 earnings materials; how they stack up against the prior-year run rate and any guide published with the release will shape the near-term debate.
By the numbers
- Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%
- Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period.
- Reported net income of $15.3 million.
- Reported positive Adjusted EBITDA of $44.4 million.
- Reported net cash used in operating activities of $22.2 million, and free cash flow of $(39.7) million.
- Share repurchase program of up to $100.0 million, of which $72.1 million remains available for repurchase under the existing Board authorization.
Sources
- Caris Life Sciences, Inc. Form 8-K with quarterly financial results, filed 2026-11-04 (accession 0002019410-26-000067)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.